The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Open accessPreprint — published as 10.1038/s41541-023-00751-6 · Paper page
Abstract
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4°C. Moreover, Pfizer-BioNTech’s 5’ UTR and Moderna’s 3’ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Flagged first, then by citations
Metadata
- Authors
- Zhang, L., More, K., Ojha, A., Jackson, C., Quinlan, B., Li, H., He, W., Farzan, M., Pardi, N., & Choe, H.
- Affiliations
- Boston Children's Hospital (US)
- The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (US)
- Scripps Research Institute (US)
- Broad Institute (US)
- University of Pennsylvania (US)
- Corresponding author
- Zhang, Lizhou
- Choe, Hyeryun
- ORCID
- Venue
- npj Vaccines
- Published
- 2023-08-03
- Volume
- 8
- Issue
- 1
- Pages
- 156-156
- ISSN
- 2059-0105 (ISSN-L)
- PMC
- PMC10567765
- OpenAlex
- W4387526062
- Cited by
- 243
- References
- 3
- Citations by year
- 2026: 85 · 2025: 110 · 2024: 45 · 2023: 3
- FWCI
- 21.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- npj Vaccines (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Foundation for the National Institutes of Health (R01 AI129868)
- University of Pennsylvania
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI129868)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- COVID-19 vaccines, mRNA-LNP vaccine, ionizable lipids, SM-102, ALC-0315, 5' untranslated region, 3' untranslated region, N1-methylpseudouridine, wobble position, nucleoside-modified mRNA, mRNA delivery, antibody response, vaccine stability, SARS-CoV-2 spike protein, BNT162b2, Moderna vaccine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
